Objective: The aim of this study was to develop an immunomagnetic/real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay and assess its clinical value for the molecular detection of circulating tumor cells (CTCs) in peripheral blood of pancreatic cancer patients. Methods: The presence of CTCs was evaluated in 34 pancreatic cancer patients before systemic therapy and in 40 healthy controls, through immunomagnetic enrichment, using the antibodies BM7 and VU1D9 [targeting mucin 1 and epithelial cell adhesion molecule (EpCAM), respectively], followed by real-time RT-PCR analysis of the genes KRT19, MUC1, EPCAM, CEACAM5 and BIRC5. Results: The developed assay showed high specificity, as none of the healthy controls were found to be positive for the multimarker gene panel. CTCs were detected in 47.1% of the pancreatic cancer patients before the beginning of systemic treatment. Shorter median progression-free survival (PFS) was observed for patients who had at least one detectable tumor-associated transcript, compared with patients who were CTC negative. Median PFS time was 66.0 days [95% confidence interval (CI) 44.8–87.2] for patients with baseline CTC positivity and 138.0 days (95% CI 124.1–151.9) for CTC-negative patients (p = 0.01, log-rank test). Conclusion: Our results suggest that in addition to the current prognostic methods, CTC analysis represents a potential complementary tool for prediction of outcome in pancreatic cancer patients.

Keywords:
Pancreatic cancer, Reverse transcriptase real-time polymerase chain reaction, Circulating tumor cells
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
3.
Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al: MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011;30:1449–1459.
4.
Ishizone S, Yamauchi K, Kawa S, Suzuki T, Shimizu F, Harada O, et al: Clinical utility of quantitative RT-PCR targeted to alpha1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Sci 2006;97:119–126.
5.
Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920–928.
6.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–791.
7.
Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al: Circulating tumor cells versus imaging – predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403–6409.
8.
Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213–3221.
9.
Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009;20:1223–1229.
10.
Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233–239.
11.
Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, et al: Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med 2009;15:101–114.
12.
Bidard FC, Ferrand FR, Huguet F, Hammel P, Louvet C, Malka D, et al: Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol 2011, E-pub ahead of print.
13.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
14.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611–622.
15.
Caraguel CGB, Stryhn H, Gagné N, Dohoo IR, Hammell KL: Selection of a cutoff value for real-time polymerase chain reaction results to fit a diagnostic purpose: analytical and epidemiologic approaches. J Vet Diagn Invest 2011;23:2–15.
16.
Martin EW Jr, James KK, Hurtubise PE, Catalano P, Minton JP: The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer 1977;39:440–446.
17.
Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462–468.
18.
Harmenberg U, Wahren B, Wiechel KL: Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988;48:1985–1988.
19.
Bluemke DA, Abrams RA, Yeo CJ, Cameron JL, Fishman EK: Recurrent pancreatic adenocarcinoma: spiral CT evaluation following the Whipple procedure. Radiographics 1997;17:303–313.
20.
Heiken JP, Balfe DM, Picus D, Scharp DW: Radical pancreatectomy: postoperative evaluation by CT. Radiology 1984;153:211–215.
21.
Takeuchi H, Kitagawa Y: Circulating tumor cells in gastrointestinal cancer. J Hepatobiliary Pancreat Sci 2010;17:577–582.
22.
Vogel I, Kalthoff H, Henne-Bruns D, Kremer B: Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. Pancreatology 2002;2:79–88.
23.
Hoffmann K, Kerner C, Wilfert W, Mueller M, Thiery J, Hauss J, et al: Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007;13:257–263.
24.
Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235–1239.
25.
Soeth E, Grigoleit U, Moellmann B, Röder C, Schniewind B, Kremer B, et al: Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol 2005;131:669–676.
26.
Zhou J, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM: Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res 2011;171:631–636.
27.
Sergeant G, Roskams T, van Pelt J, Houtmeyers F, Aerts R, Topal B: Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer 2011;11:47.
28.
Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al: Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122–128.
29.
Tai K-Y, Shiah S-G, Shieh Y-S, Kao Y-R, Chi C-Y, Huang E, et al: DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 2007;26:3989–3997.
30.
Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al: High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207–213.
31.
Koyanagi K, Bilchik AJ, Saha S, Turner RR, Wiese D, McCarter M, et al: Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res 2008;14:7391–7396.
32.
Mocellin S, Keilholz U, Rossi CR, Nitti D: Circulating tumor cells: the ‘leukemic phase’ of solid cancers. Trends Mol Med 2006;12:130–139.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.